- Home
- NMCO vs ARCT Comparison
NMCO vs ARCT Comparison
Compare NMCO & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMCO | ARCT |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 549.9M | 163.4M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NMCO | ARCT |
|---|---|---|
| Price | $8.75 | $13.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $23.20 |
| AVG Volume (30 Days) | 498.9K | ★ 782.1K |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $58.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.65 | $5.50 |
| 52 Week High | $11.00 | $24.14 |
Technical Indicators
Market Signals| Indicator | NMCO | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 25.34 | 48.74 |
| Support Level | N/A | $13.12 |
| Resistance Level | $10.83 | $17.85 |
| Average True Range (ATR) | 0.19 | 1.20 |
| MACD | -0.07 | -0.43 |
| Stochastic Oscillator | 8.04 | 7.32 |
Price Performance
Historical ComparisonAbout NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.